(Q37844364)

24 August 2017

1 reference

title

Febuxostat for treatment of chronic gout (English)

1 reference

24 August 2017

Charnelda L Gray

1

1 reference

24 August 2017

Nafesa E Walters-Smith

series ordinal

2

1 reference

24 August 2017

publication date

1 March 2011

1 reference

American Journal of Health-System Pharmacy

24 August 2017

published in

1 reference

24 August 2017

volume

68

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

389-398

1 reference

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Preliminary criteria for the classification of the acute arthritis of primary gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Gout--what are the treatment options?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

31 March 2020

Metabolic diseases: gout

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Newer therapeutic approaches: gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Uricosuric effect of losartan in patients with renal transplants.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Ascorbic acid-induced uricosuria. A consequency of megavitamin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

31 March 2020

The management of gout

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Emerging therapies in the long-term management of hyperuricaemia and gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100394

31 March 2020

Identifiers

DOI

10.2146/AJHP100394

1 reference

24 August 2017

1 reference